Vitamin D and the Immune System

维生素 D 和免疫系统

• 批准号: 8716342
• 负责人: SYLVIA S CHRISTAKOS
• 金额: $ 0.31万
• 依托单位: RBHS-NEW JERSEY MEDICAL SCHOOL
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-03-01 至 2014-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8716342
• 关键词: Vitamin; Immune; System

DESCRIPTION (provided by applicant): Our preliminary results have shown a direct suppression of IL-17 by 1,25(OH)2D3 as well as reversal of paralysis and inhibition of progression of EAE [a murine model of multiple sclerosis (MS)] by 1,25(OH)2D3 which is associated with an inhibition of IL-17. We propose to examine the mechanisms involved. We hypothesize that understanding the mechanisms involved will result in new concepts in our understanding of the interaction between the vitamin D endocrine system and the immune system that may suggest therapeutic targets for the control of MS and other TH17 dependent inflammatory diseases including inflammation induced bone loss. In Specific Aim 1 we will examine the effect of in vivo treatment of EAE mice with 1,25(OH)2D3 on the production of IL-17 and other cytokines (brains and spinal cords as well as splenocytes and lymph nodes will be isolated from EAE mice and the effect of 1,25(OH)2D3 on the production of various cytokines including those produced by TH17 cells (IL-17A, IL-17F, IL-21, IL-22), TH2 cells (IL-4, IL-5), regulatory T cells (IL-10 and TGF?) and innate immune cells (IL-23, IL-12, IL6 and the anti-inflammatory cytokine, IL-27) will be assessed. In preliminary results we noted for the first time that 1,25(OH)2D3 has a direct inhibitory effect on activated IL-17 expression and transcription. The mechanisms involved will be examined (1,25(OH)2D3 may mediate this repression by inhibiting activation mediated by NFAT, Runx1 and ROR gamma transcription factors). Genome-wide analysis of NFAT, Runx1 and vitamin D receptor (VDR) binding sites in CD4+T cell DNA isolated from EAE mice treated with vehicle or 1,25(OH)2D3 using ChIP-seq will also be done. These studies will enable us to identify new target genes and to assess how functional relationship among genes involved in immune function may be altered after 1,25(OH)2D3 treatment. These studies would provide mechanisms for the reversal of paralysis by 1,25(OH)2D3. It is possible that the mechanisms we identify may reflect more general mechanisms involved in a therapeutic role of 1,25(OH)2D3 in the control of pathological immune responses. In Specific Aim 2, since clinical studies are being done treating MS patients with high dose vitamin D, we also propose to examine the effect of high dose dietary vitamin D on paralysis, on the progression of EAE and the production of IL-17 and other cytokines. These studies provide a unique opportunity to combine the expertise of the Steinman lab in multiple sclerosis and immunology and the Christakos lab in vitamin D to increase our understanding of the interaction between the vitamin D endocrine system and the immune system. Findings from these studies may suggest new therapeutic targets and treatment strategies for MS and other TH17 dependent inflammatory diseases. This application is appropriate for the R21 mechanism which supports projects that "involve considerable risk but may lead to a breakthrough in a particular area that could have a major impact on a field of biomedical or clinical research."

描述（由申请人提供）：我们的初步结果表明，1，25（OH）2D 3直接抑制IL-17，以及1，25（OH）2D 3逆转瘫痪和抑制EAE [多发性硬化症（MS）的鼠模型]的进展，这与IL-17的抑制有关。我们建议审查有关机制。我们假设，了解所涉及的机制将导致我们对维生素D内分泌系统和免疫系统之间相互作用的理解产生新的概念，这可能表明控制MS和其他TH 17依赖性炎症性疾病（包括炎症诱导的骨丢失）的治疗靶点。在具体目标1中，我们将检查用1，25（OH）2D 3体内治疗EAE小鼠对IL-17和其他细胞因子产生的影响（将从EAE小鼠中分离脑和脊髓以及脾细胞和淋巴结，并研究1，25（OH）2D 3对各种细胞因子（包括由TH 17细胞产生的细胞因子）产生的影响（IL-17 A、IL-17 F、IL-21、IL-22）、TH 2细胞（IL-4、IL-5）、调节性T细胞（IL-10和TGF？）并评估先天免疫细胞（IL-23、IL-12、IL-6和抗炎细胞因子IL-27）。在初步结果中，我们首次注意到1，25（OH）2D 3对活化的IL-17表达和转录具有直接抑制作用。将检查所涉及的机制（1，25（OH）2D 3可能通过抑制NFAT、Runx 1和ROR γ转录因子介导的激活来介导这种抑制）。还将使用ChIP-seq对从用溶剂或1，25（OH）2D 3处理的EAE小鼠中分离的CD 4 +T细胞DNA中的NFAT、Runx 1和维生素D受体（VDR）结合位点进行全基因组分析。这些研究将使我们能够确定新的靶基因，并评估1，25（OH）2D 3治疗后参与免疫功能的基因之间的功能关系如何改变。这些研究将提供1，25（OH）2D 3逆转瘫痪的机制。我们确定的机制可能反映了1，25（OH）2D 3在控制病理性免疫反应中的治疗作用所涉及的更一般的机制。在具体目标2中，由于正在进行用高剂量维生素D治疗MS患者的临床研究，我们还建议检查高剂量膳食维生素D对瘫痪、对EAE进展以及IL-17和其他细胞因子产生的影响。这些研究为联合收割机提供了一个独特的机会，将Steinman实验室在多发性硬化症和免疫学方面的专业知识与Christakos实验室在维生素D方面的专业知识结合起来，以增加我们对维生素D内分泌系统和免疫系统之间相互作用的理解。这些研究结果可能为MS和其他TH 17依赖性炎症性疾病提供新的治疗靶点和治疗策略。该申请适用于R21机制，该机制支持“涉及相当大的风险，但可能导致在特定领域取得突破，可能对生物医学或临床研究领域产生重大影响的项目。"